Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Among authors: goto h. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
Miyata Y, Yakushijin K, Inui Y, Imamura Y, Goto H, Mizutani Y, Kurata K, Kakiuchi S, Sanada Y, Minami Y, Kawamoto S, Yamamoto K, Ito M, Tominaga R, Gomyo H, Mizuno I, Nomura T, Kitagawa K, Sugimoto T, Murayama T, Matsuoka H, Minami H. Miyata Y, et al. Among authors: goto h. Int J Hematol. 2016 Dec;104(6):682-691. doi: 10.1007/s12185-016-2089-9. Epub 2016 Sep 9. Int J Hematol. 2016. PMID: 27612464 Clinical Trial.
An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
Mizutani Y, Inase A, Maimaitili Y, Miyata Y, Kitao A, Matsumoto H, Kawaguchi K, Higashime A, Goto H, Kurata K, Yakushijin K, Minami H, Matsuoka H. Mizutani Y, et al. Among authors: goto h. Int J Hematol. 2019 Oct;110(4):490-499. doi: 10.1007/s12185-019-02701-2. Epub 2019 Jul 8. Int J Hematol. 2019. PMID: 31286402
GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.
Inase A, Maimaitili Y, Kimbara S, Mizutani Y, Miyata Y, Ohata S, Matsumoto H, Kitao A, Sakai R, Kawaguchi K, Higashime A, Nagao S, Kurata K, Goto H, Kawamoto S, Yakushijin K, Minami H, Matsuoka H. Inase A, et al. Among authors: goto h. EJHaem. 2022 Dec 12;4(1):153-164. doi: 10.1002/jha2.600. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819180 Free PMC article.
Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Suzuki C, Kiyota N, Imamura Y, Goto H, Suto H, Chayahara N, Toyoda M, Ito Y, Miya A, Miyauchi A, Teshima M, Otsuki N, Nibu KI, Minami H. Suzuki C, et al. Among authors: goto h. Front Oncol. 2021 Jul 8;11:638123. doi: 10.3389/fonc.2021.638123. eCollection 2021. Front Oncol. 2021. PMID: 34307122 Free PMC article.
3,629 results